Faculty Opinions recommendation of Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial.

2013 ◽  
Author(s):  
Charles Coddington
Keyword(s):  
Randomized Trial ◽  
Ovarian Failure ◽  
Gonadotropin Releasing Hormone ◽  
Prospective Randomized Trial ◽  
Releasing Hormone ◽  
Gonadotropin Releasing Hormone Agonist

Gonadotropin-Releasing Hormone Agonist for the Prevention of Chemotherapy-Induced Ovarian Failure in Patients With Lymphoma: 1-Year Follow-Up of a Prospective Randomized Trial

2013 ◽  
Vol 31 (7) ◽  
pp. 903-909 ◽  
Author(s):  
Isabelle Demeestere ◽  
Pauline Brice ◽  
Fedro A. Peccatori ◽  
Alain Kentos ◽  
Isabelle Gaillard ◽  
...  
Keyword(s):  
Ovarian Function ◽  
Alkylating Agents ◽  
Prospective Trial ◽  
Young Patients ◽  
Ovarian Failure ◽  
Gonadotropin Releasing Hormone ◽  
Control Group ◽  
Releasing Hormone ◽  
Gonadotropin Releasing Hormone Agonist

Purpose To assess the efficacy of gonadotropin-releasing hormone agonist (GnRHa) in preventing chemotherapy-induced ovarian failure in patients treated for Hodgkin or non-Hodgkin lymphoma within the setting of a multicenter, randomized, prospective trial. Patients and Methods Patients age 18 to 45 years were randomly assigned to receive either the GnRHa triptorelin plus norethisterone (GnRHa group) or norethisterone alone (control group) concomitantly with alkylating agents containing chemotherapy. The primary end point was the premature ovarian failure (POF) rate (follicle-stimulating hormone [FSH] ≥ 40 IU/L) after 1 year of follow-up. Results Eighty-four of 129 randomly assigned patients completed the 1-year follow-up. The mean FSH values were higher in the control group than in the GnRHa group during chemotherapy; however, this difference was no longer observed after 6 months of follow-up. After 1 year, 20% and 19% of patients in the GnRHa and control groups, respectively, exhibited POF (P = 1.00). More than half of patients in each group completely restored their ovarian function (FSH < 10 IU/L), but the anti–Müllerian hormone values were higher in the GnRHa group than in the control group (1.4 ± 0.35 v 0.5 ± 0.15 ng/mL, respectively; P = .040). The occurrence of adverse events was similar in both groups with the exception of metrorrhagia, which was more frequently observed in the control group than the GnRHa group (38.4% v 15.6%, respectively; P = .024). Conclusion Approximately 20% of patients in both groups exhibited POF after 1 year of follow-up. Triptorelin was not associated with a significant decreased risk of POF in young patients treated for lymphoma but may provide protection of the ovarian reserve.

A Prospective, Randomized Trial of Gonadotropin-Releasing Hormone Agonist Plus Estrogen-Progestin or Progestin “Add-Back” Regimens for Women With Leiomyomata Uteri

1994 ◽  
Vol 49 (1) ◽  
pp. 37-39
Author(s):  
Andrew J. Friedman ◽  
Margaret Daly ◽  
Mary Juneau-Norcross ◽  
Mitchell S. Rein ◽  
Calliope Fine ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Gonadotropin Releasing Hormone ◽  
Prospective Randomized Trial ◽  
Releasing Hormone ◽  
Gonadotropin Releasing Hormone Agonist

NEOADJUVANT GONADOTROPIN-RELEASING HORMONE THERAPY BEFORE SURGERY MAY IMPROVE THE FERTILITY INDEX IN UNDESCENDED TESTES: A PROSPECTIVE RANDOMIZED TRIAL

2005 ◽  
Vol 173 (3) ◽  
pp. 974-977 ◽  
Author(s):  
CHRISTIAN SCHWENTNER ◽  
JOSEF OSWALD ◽  
ALFONS KRECZY ◽  
ANDREAS LUNACEK ◽  
GEORG BARTSCH ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Hormone Therapy ◽  
Gonadotropin Releasing Hormone ◽  
Prospective Randomized Trial ◽  
Undescended Testes ◽  
Releasing Hormone ◽  
Fertility Index
Sign in / Sign up

Export Citation Format

Share Document